MYX mayne pharma group limited

Ann: 2022 Full Year Media Release, page-12

  1. 1,472 Posts.
    lightbulb Created with Sketch. 290
    A few more years relying on our big ticket products that need to do exceptionally well given what they cost us and hopefully go on developing / buying commercializing new products praying they'll do well enough to interest some entity will take us over . So much for company's growth which cost early shareholders dearly in both monetary and years waiting in vain hoping to see company post a net profit that never happened . Now Mayne's unsustainable growth in the US now sold and proceeds used to pay down out of control debt and hair brained decision to squander a good part of it on some special dividend which will amount to almost nothing considering the number of holders on board now a penny stock . Well done board .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.01
Change
-0.070(1.38%)
Mkt cap ! $407.0M
Open High Low Value Volume
$5.08 $5.10 $4.95 $436.1K 87.05K

Buyers (Bids)

No. Vol. Price($)
6 1620 $5.01
 

Sellers (Offers)

Price($) Vol. No.
$5.04 1512 6
View Market Depth
Last trade - 15.17pm 30/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.